cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Molecular Templates Inc
5 own
16 watching
Current Price
$0.57
$0.01
(1.79%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
32.12M
52-Week High
52-Week High
3.6365
52-Week Low
52-Week Low
0.31
Average Volume
Average Volume
0.07M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization32.12M
icon52-Week High3.6365
icon52-Week Low0.31
iconAverage Volume0.07M
iconDividend Yield--
iconP/E Ratio--
What does the Molecular Templates Inc do?
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.
Read More
How much money does Molecular Templates Inc make?
News & Events about Molecular Templates Inc.
Globe Newswire
3 months ago
AUSTIN, Texas, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc.(Nasdaq: MTEM, Molecular Templates, or MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced ...
Globe Newswire
8 months ago
Presentations on the MT-6402 (PD-L1) and MT-5111(HER2) Phase I dose escalation programs demonstrate unique biology, continued tolerability, and dose-dependent pharmacodynamic effectsAUSTIN, Texas, June 06, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM, Molecular Templates or MTEM...
Globe Newswire
10 months ago
Event will feature a presentation by David Spigel, MD, chief scientific officer of the Sarah Cannon Research Institute Wednesday, April 13th @ 8:00 am ET AUSTIN, Texas, April 08, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, Molecular Templates, or MTEM or the Company), a ...
Benzinga
10 months ago
read more...
Frequently Asked Questions
Frequently Asked Questions
What is Molecular Templates Inc share price today?
plus_minus_icon
Can Indians buy Molecular Templates Inc shares?
plus_minus_icon
How can I buy Molecular Templates Inc shares from India?
plus_minus_icon
Can Fractional shares of Molecular Templates Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Molecular Templates Inc stocks?
plus_minus_icon
What is today’s traded volume of Molecular Templates Inc?
plus_minus_icon
What is today’s market capitalisation of Molecular Templates Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Molecular Templates Inc?
plus_minus_icon
What percentage is Molecular Templates Inc down from its 52-Week High?
plus_minus_icon
What percentage is Molecular Templates Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0.57
$0.01
(1.79%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00